Danish Pharma Hopes Stand-alone Medicines Agency Will Speed Up Drug Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma group hopes DMA will clear up drug review backlog once it is separated from larger health authority.
You may also be interested in...
New Division At Danish Medicines Agency To Put Greater Focus On Benefit-Risk Issues
Major organizational changes are in store for the Danish Medicines Agency in the New Year that will aim to modernize its processes and functioning.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.